Recent developments in the search for biomarkers for the diagnosis and monitoring of diabetes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the fields of genomic, proteomic and metabolomic technologies many advances have been made in the past few years for the early diagnosis and monitoring of diseases such as diabetes mellitus. As diabetes is afflicting affluent and developing societies throughout the world and is fuelled by aging demographics and the recent increase of obesity and related insulin resistance, there is a clear need to discover effective agents for diagnosing the disease and controlling glycaemic status. Biological markers such as peptides, proteins, metabolites, nucleic acids and polymorphisms have been proposed as novel exciting biomarkers. Patents have been filed demonstrating altered levels of proteins such as pancreatic polypeptide in beta cell failure and fibronectin in insulin resistance. Much interest has focused on the potential of glycosylated proteins such as glycated insulin, glycosylated amylin, C-terminally truncated form of the receptor for advanced glycation end-products, and glycated LDL antibodies. The emergence of genomic analysis is now complemented by systems biology and computational methods that can unravel large amounts of heterogeneous genetic and genomic information to produce meaningful results. Many patents have been filed that claim to estimate the susceptibility or predisposition of metabolic disease such as diabetes. New genomic technologies such as transcriptional profiling and proteomics have been shown to be significant in identifying and validating biomarkers, and systems biology has shown great promise in unravelling the complexities of genomic, proteomic and metabolomic technologies.
LanguageEnglish
Pages172-177
JournalRecent Patents on Endocrine, Metabolic & Immune Drug Discovery
Volume2
Issue number3
Publication statusPublished - 2008

Fingerprint

Proteomics
Metabolomics
Systems Biology
Patents
Biomarkers
Technology
Insulin Resistance
Islet Amyloid Polypeptide
Pancreatic Polypeptide
Proteins
Metabolic Diseases
Population Dynamics
Fibronectins
Nucleic Acids
Early Diagnosis
Diabetes Mellitus
Obesity
Peptides
Antibodies
glycosylated insulin

Cite this

@article{939221ba09144ae49a4eaf54426d5cf2,
title = "Recent developments in the search for biomarkers for the diagnosis and monitoring of diabetes",
abstract = "In the fields of genomic, proteomic and metabolomic technologies many advances have been made in the past few years for the early diagnosis and monitoring of diseases such as diabetes mellitus. As diabetes is afflicting affluent and developing societies throughout the world and is fuelled by aging demographics and the recent increase of obesity and related insulin resistance, there is a clear need to discover effective agents for diagnosing the disease and controlling glycaemic status. Biological markers such as peptides, proteins, metabolites, nucleic acids and polymorphisms have been proposed as novel exciting biomarkers. Patents have been filed demonstrating altered levels of proteins such as pancreatic polypeptide in beta cell failure and fibronectin in insulin resistance. Much interest has focused on the potential of glycosylated proteins such as glycated insulin, glycosylated amylin, C-terminally truncated form of the receptor for advanced glycation end-products, and glycated LDL antibodies. The emergence of genomic analysis is now complemented by systems biology and computational methods that can unravel large amounts of heterogeneous genetic and genomic information to produce meaningful results. Many patents have been filed that claim to estimate the susceptibility or predisposition of metabolic disease such as diabetes. New genomic technologies such as transcriptional profiling and proteomics have been shown to be significant in identifying and validating biomarkers, and systems biology has shown great promise in unravelling the complexities of genomic, proteomic and metabolomic technologies.",
author = "Aine McKillop and Peter Flatt",
year = "2008",
language = "English",
volume = "2",
pages = "172--177",
journal = "Recent Patents on Endocrine, Metabolic & Immune Drug Discovery",
issn = "1872-2148",
number = "3",

}

TY - JOUR

T1 - Recent developments in the search for biomarkers for the diagnosis and monitoring of diabetes

AU - McKillop, Aine

AU - Flatt, Peter

PY - 2008

Y1 - 2008

N2 - In the fields of genomic, proteomic and metabolomic technologies many advances have been made in the past few years for the early diagnosis and monitoring of diseases such as diabetes mellitus. As diabetes is afflicting affluent and developing societies throughout the world and is fuelled by aging demographics and the recent increase of obesity and related insulin resistance, there is a clear need to discover effective agents for diagnosing the disease and controlling glycaemic status. Biological markers such as peptides, proteins, metabolites, nucleic acids and polymorphisms have been proposed as novel exciting biomarkers. Patents have been filed demonstrating altered levels of proteins such as pancreatic polypeptide in beta cell failure and fibronectin in insulin resistance. Much interest has focused on the potential of glycosylated proteins such as glycated insulin, glycosylated amylin, C-terminally truncated form of the receptor for advanced glycation end-products, and glycated LDL antibodies. The emergence of genomic analysis is now complemented by systems biology and computational methods that can unravel large amounts of heterogeneous genetic and genomic information to produce meaningful results. Many patents have been filed that claim to estimate the susceptibility or predisposition of metabolic disease such as diabetes. New genomic technologies such as transcriptional profiling and proteomics have been shown to be significant in identifying and validating biomarkers, and systems biology has shown great promise in unravelling the complexities of genomic, proteomic and metabolomic technologies.

AB - In the fields of genomic, proteomic and metabolomic technologies many advances have been made in the past few years for the early diagnosis and monitoring of diseases such as diabetes mellitus. As diabetes is afflicting affluent and developing societies throughout the world and is fuelled by aging demographics and the recent increase of obesity and related insulin resistance, there is a clear need to discover effective agents for diagnosing the disease and controlling glycaemic status. Biological markers such as peptides, proteins, metabolites, nucleic acids and polymorphisms have been proposed as novel exciting biomarkers. Patents have been filed demonstrating altered levels of proteins such as pancreatic polypeptide in beta cell failure and fibronectin in insulin resistance. Much interest has focused on the potential of glycosylated proteins such as glycated insulin, glycosylated amylin, C-terminally truncated form of the receptor for advanced glycation end-products, and glycated LDL antibodies. The emergence of genomic analysis is now complemented by systems biology and computational methods that can unravel large amounts of heterogeneous genetic and genomic information to produce meaningful results. Many patents have been filed that claim to estimate the susceptibility or predisposition of metabolic disease such as diabetes. New genomic technologies such as transcriptional profiling and proteomics have been shown to be significant in identifying and validating biomarkers, and systems biology has shown great promise in unravelling the complexities of genomic, proteomic and metabolomic technologies.

M3 - Article

VL - 2

SP - 172

EP - 177

JO - Recent Patents on Endocrine, Metabolic & Immune Drug Discovery

T2 - Recent Patents on Endocrine, Metabolic & Immune Drug Discovery

JF - Recent Patents on Endocrine, Metabolic & Immune Drug Discovery

SN - 1872-2148

IS - 3

ER -